Our lead product candidate, NP001, is a novel, proprietary investigational therapy that regulates activated macrophages associated with chronic neurologic diseases including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. In a Phase 2a safety, tolerability and preliminary efficacy study enrolling 136 patients, NP001 demonstrated a clinically relevant slowing of ALS progression in a subset of patients treated over a 6-month period, with a favorable safety and tolerability profile. The most common adverse events were dizziness and injection site pain. Neuraltus plans to initiate an additional Phase 2 study of NP001 in ALS patients during 2016. Further details about the trial will be announced at the start of the study.